It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Isomerases perform biotransformations without cofactors but often cause an undesirable mixture of substrate and product due to unfavorable thermodynamic equilibria. We demonstrate the feasibility of using an engineered yeast strain harboring oxidoreductase reactions to overcome the thermodynamic limit of an isomerization reaction. Specifically, a yeast strain capable of consuming lactose intracellularly is engineered to produce tagatose from lactose through three layers of manipulations. First, GAL1 coding for galactose kinase is deleted to eliminate galactose utilization. Second, heterologous xylose reductase (XR) and galactitol dehydrogenase (GDH) are introduced into the ∆gal1 strain. Third, the expression levels of XR and GDH are adjusted to maximize tagatose production. The resulting engineered yeast produces 37.69 g/L of tagatose from lactose with a tagatose and galactose ratio of 9:1 in the reaction broth. These results suggest that in vivo oxidoreaductase reactions can be employed to replace isomerases in vitro for biotransformation.
A desired product cannot be obtained at higher concentration than its equilibrium concentration when isomerases are used for biotransformation. Here, the authors engineer in vivo oxidoreductive reactions in yeast to overcome the equilibrium limitation of in vitro isomerases-based tagatose production.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details



1 University of Illinois at Urbana-Champaign, Carl R. Woese Institute for Genomic Biology, Urbana, USA (GRID:grid.35403.31) (ISNI:0000 0004 1936 9991)
2 University of Illinois at Urbana-Champaign, Carl R. Woese Institute for Genomic Biology, Urbana, USA (GRID:grid.35403.31) (ISNI:0000 0004 1936 9991); University of Illinois at Urbana-Champaign, Department of Food Science and Human Nutrition, Urbana, USA (GRID:grid.35403.31) (ISNI:0000 0004 1936 9991)
3 University of Illinois at Urbana-Champaign, Carl R. Woese Institute for Genomic Biology, Urbana, USA (GRID:grid.35403.31) (ISNI:0000 0004 1936 9991); Korea University, Department of Biotechnology, Graduate School, Seoul, South Korea (GRID:grid.222754.4) (ISNI:0000 0001 0840 2678)
4 National Center for Genetic Engineering and Biotechnology (BIOTEC), Pathum Thani, Thailand (GRID:grid.419250.b)
5 University of California, Department of Molecular and Cell Biology, Berkeley, USA (GRID:grid.47840.3f) (ISNI:0000 0001 2181 7878)